Merck’s Keytruda could become a national tourist attraction in China, with a special approval for imports to the resort island of Hainan.

Sanofi and Regeneron’s next wannabe blockbuster is officially in regulators’ hands--but with the candidate tapped for a speedy review process, it may not stay…

Pfizer CEO Ian Read has been dropping hints like bread crumbs, and now it's official: The company has decided not to split up. Cue the wailing from…

If Bayer's proposed $66 billion purchase of Monsanto goes through, Bayer is considering dropping the Monsanto name.

Vanda is a small drugmaker. Its two central nervous system drugs generated only about $100 million in sales last year. But with lots of M&A dollars being…

Novartis has some new data in hand that could potentially help cancer med Zykadia snag a first-line indication in ALK+ non-small cell lung cancer. But a rival…

Thirty-five U.S. states and the District of Columbia have filed suit against the U.K.'s Indivior, alleging anticompetitive actions for the opioid Suboxone…

Endo has struggled lately to right the ship, and now it’s giving a new skipper a turn at the wheel.